Tandem Diabetes (TNDM) Care Announces Control-IQ Technology Meta-analysis Demonstrating Positive Clinical Impact of Automatic Correction Bolusing on Glucose Control in People with Type 1 Diabetes streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today announced publication by Diabetes Technology & Therapeutics of a meta-analysis of three randomized. | April 17, 2023
Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with Control-IQ Technology streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Research shows that closed-loop systems can increase time in range and reduce both hyperglycemia and hypoglycemia in youth and young adults.<br />
Hybrid closed-loop insulin therapy improves glycemic control in adolescents, young adults
Hybrid closed-loop insulin therapy improved glycemic control in adolescents and young adults with type 1 diabetes. These outcomes, derived from the International Diabetes Closed-Loop (iDCL) Trial, are reported in the peer-reviewed journal
Diabetes Technology & Therapeutics (DTT).
Adolescents and young adults with a mean age of 17 years were randomly assigned to a closed-loop control (CLC) insulin delivery system or a sensor augmented pump (SAP) with a continuous glucose monitoring system over a 6-month period. The Time in Range increased by 13% for the CLC group, compared to a decrease of 1% with SAP, for a group difference of +3.1 hours/day. This reflected a reduction in time spent at >180 mg/dL. The use of CLC was especially effective at increasing Time in Range overnight.